Norges Bank Takes $12.83 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Norges Bank acquired a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMRFree Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 504,083 shares of the company’s stock, valued at approximately $12,834,000. Norges Bank owned approximately 0.91% of Kymera Therapeutics as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KYMR. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Kymera Therapeutics by 2.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,940 shares of the company’s stock valued at $584,000 after purchasing an additional 524 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in Kymera Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after buying an additional 1,866 shares during the last quarter. Barclays PLC increased its position in Kymera Therapeutics by 1.2% in the 3rd quarter. Barclays PLC now owns 389,476 shares of the company’s stock worth $5,414,000 after buying an additional 4,493 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Kymera Therapeutics by 1.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 306,692 shares of the company’s stock worth $7,808,000 after buying an additional 4,951 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after acquiring an additional 5,002 shares during the period.

Kymera Therapeutics Trading Up 1.2 %

KYMR opened at $31.94 on Wednesday. Kymera Therapeutics, Inc. has a 1-year low of $9.60 and a 1-year high of $45.31. The firm has a 50-day moving average price of $35.71 and a two-hundred day moving average price of $32.87. The stock has a market capitalization of $1.96 billion, a PE ratio of -12.73 and a beta of 2.25.

Kymera Therapeutics (NASDAQ:KYMRGet Free Report) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. The firm had revenue of $10.30 million during the quarter, compared to analysts’ expectations of $14.24 million. Kymera Therapeutics had a negative net margin of 194.67% and a negative return on equity of 31.92%. Kymera Therapeutics’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.70) EPS. On average, research analysts predict that Kymera Therapeutics, Inc. will post -2.86 EPS for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the transaction, the director now directly owns 806,697 shares of the company’s stock, valued at $32,638,960.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the sale, the director now directly owns 806,697 shares in the company, valued at approximately $32,638,960.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $42.23, for a total transaction of $4,860,250.70. Following the completion of the transaction, the insider now owns 4,676,075 shares of the company’s stock, valued at approximately $197,470,647.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 419,595 shares of company stock worth $17,650,436. Insiders own 15.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on KYMR shares. HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of Kymera Therapeutics in a research note on Monday. Piper Sandler lifted their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 27th. Oppenheimer cut their price target on Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Truist Financial lifted their target price on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, JPMorgan Chase & Co. upped their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.70.

View Our Latest Research Report on Kymera Therapeutics

About Kymera Therapeutics

(Free Report)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

See Also

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.